High-dose alfacalcidol improves anaemia in patients on haemodialysis

Nephrology Dialysis Transplantation

Volumn 12, Issue 3, 1997, Pages 514-518

  Albitar, S ^a   Genin, R ^a   Fen Chong, M ^a   Serveaux, M O ^a   Schohn, D ^a   Chuet, C ^a  

^a Centre Hospitalier Departemental Felix Guyon   (France)

Author keywords

Anaemia; Haemodialysis; High dose alfacalcidol; Moderate hyperparathyroidism

Indexed keywords

ALFACALCIDOL; ALUMINUM; CALCIUM; CALCIUM CARBONATE; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VITAMIN D;

ADULT; AGED; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; HEMATOPOIETIC TISSUE; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERCALCEMIA; KIDNEY FAILURE; MALE; ORAL DRUG ADMINISTRATION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE COUNT; SECONDARY HYPERPARATHYROIDISM;

ADULT; ANEMIA; ERYTHROPOIESIS; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0031049247     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.3.514     Document Type: Article

References (16)

1. Winearls CG, Oliver D, Pipprad MG et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic dialysis. Lancet 1986; 2:1175-1177
2. Kjihn K, Nonnast-Daniel B, Griitzmacher P et al. Analysis of initial resistance of erythropoiesis to treatment with recombinant erythropoietin. Contrib Nephrol 1988; 66: 94-103
3. Albitar S, Meulders Q, Hammond H et al. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995; 10: s40-43
4. Albitar S, Meulders Q, Soutif C et al. High dose 1-OH vitamin D anaemia in haemodialysed population in the absence of erythropoietin: Nephrol Dial Transplant 1994; 9: 7
5. Argilis A, Lorho R, Mourad G, Mion C. High-dose alfacalcidol for anaemia in dialysis:Lancet 1993; 347: 378-379
6. Carozzi S, Ramello A, Nasini MG et al. Ca ++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients. Adv Perit Dial 1990; 6: 312-315
7. Goicoechea M, Gomez-Campdera F, Polo JR et al. Secondary hyperparathyroidism as a cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. Clin Nephrol 1996; 45: 420-421
8. Urena P, Eckard KU, Sarfati E et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron 1991; 59: 384-393
9. Bia M, Cooper K, Schnall S et al. Aluminium induced anemia: pathogenesis and treatment in patients on chronic renal failure. Kidney Int 1989; 36: 852-858
10. Kelsey SM, Newland AC, Cunnigham J et al. Sustained haematological response to high dose alfacalcidol in patients with myeloplastic syndromes. Lancet 1992; 340: 316-317
11. Imai Y, Tsutsumi M, Tsunenari T et al. Therapeutic trial of haematological disorders with intermittent administration of high-dose of 1-alpha-hydroxyvitamin D3. Contrib Nephrol 1991; 91: 95-101
12. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminium: The roleof suppressed parathyroid function. Kidney Int 1993; 44: 860-866
13. Moriniere P, Cohen-Solal M, Beibrik S et al. Disappearance of aluminic bone disease in along-term asymptomatic dialysis population restricting Al (OH) 3 intake: emergence of an idiopathic adynamic bone disease not related to aluminium. Nephron 1989; 53: 93-101
14. Quarles LD, Yohay DA, Caroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
15. Daugirdas JT. The post/pre plasma urea nitrogen ratio to estimate Kt/V and ripCR:validation. Int J Artif Organs 1989; 12: 420-427
16. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28: 526-534